Amfetamine extended-release - Tris Pharma

Drug Profile

Amfetamine extended-release - Tris Pharma

Alternative Names: Amfetamine XR - Tris Pharma; DyanavelXR; TRI 102

Latest Information Update: 27 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tris Pharma
  • Class Amphetamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder
  • Discontinued Diabetes mellitus

Most Recent Events

  • 11 Feb 2017 Tris Pharma initiates enrolment in a phase III trial for Attention-deficit hyperactivity disorder (In children) in USA (NCT03088267)
  • 09 Feb 2017 The approved US label for Amfetamine extended release - Tris Pharma carries a black box warning related to abuse and dependence
  • 09 Feb 2017 Adverse events and efficacy data from a phase III trial in Attention-deficit hyperactivity disorder released by Tris Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top